May 15, 2001Annals of Internal Medicine
Angiotensinogen Mutations and Risk for Ischemic Heart Disease, Myocardial Infarction, and Ischemic Cerebrovascular Disease: Six Case–Control Studies from the Copenhagen City Heart Study
Why the study?
Are M235T and T174M angiotensinogen mutations associated with increased risk of ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease?
Population
11,719 participants, including patients with ischemic heart disease, myocardial infarction, or ischemic…
Comparison
Presence of M235T and T174M angiotensinogen… vs Absence of these mutations
Design
Case-control
Authors
Discussion
Loading...
Member takes
Implication
No consistent association with ischemic events; challenges prior reports and leaves open confirmation in larger studies.
Structured PICO
Are M235T and T174M angiotensinogen mutations associated with increased risk of ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease?
P
Population
11,719 participants, including patients with ischemic heart disease (n=1,809), myocardial infarction (n=1,012), or ischemic cerebrovascular disease (n=923), and 7,975 controls without these conditions from Copenhagen, Denmark.
I
Intervention
Presence of M235T and T174M angiotensinogen mutations
C
Comparator
Absence of these mutations (controls without the conditions)
O
Outcome
Ischemic heart disease, myocardial infarction, and ischemic cerebrovascular diseasehard clinical
The M235T and T174M angiotensinogen mutations are not consistently associated with ischemic cardiovascular events, suggesting that previously reported associations may represent chance findings.
Cite This Study
Sethi et al. (2001) studied this question.